Skip to main content

Table 3 The most common treatment-emergent adverse events during the maintenance phase (≥5.0%)

From: A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer

TEAE, n (%)

Pemetrexed/BSC (n = 28)

BSC (n = 27)

 

All Grades

Grade 3/4

All Grades

Grade 3/4

Dyspnea

2 (7.1)

0 (0.0)

4 (14.8)

1 (3.7)

Anemia

3 (10.7)

2 (7.1)a

1 (3.7)

1 (3.7)b

Chest/thorax pain

3 (10.7)

0 (0.0)

3 (11.1)

0 (0.0)

Neutropenia

2 (7.1)

2 (7.1)b

0 (0.0)

0 (0.0)

Abnormal ALT

2 (7.1)

0 (0.0)

1 (3.7)

1 (3.7)

Fatigue

1 (3.6)

0 (0.0)

2 (7.4)

1 (3.7)

Nausea

2 (7.1)

0 (0.0)

0 (0.0)

0 (0.0)

Vomiting

2 (7.1)

0 (0.0)

0 (0.0)

0 (0.0)

  1. Abbreviations: ALT = alanine aminotransferase; BSC = best supportive care; TEAE = treatment-emergent adverse event.
  2. a1 (3.6%) patient experienced grade 3 or 4 anemia that was considered by the investigator to be possibly study drug-related.
  3. bConsidered to be possibly drug-related.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us